Clinical Trial Update: Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the efficacy and safety of Flutiform pMDI in adults with mild to moderate-severe reversible asthma is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• FlutiForm (fluticasone propionate/formoterol)

Snippet

Sponsor: Mundipharma Research Limited | Conditions: Asthma Bronchiale | Phase 3 | Status: COMPLETED